Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.
about
The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stabilityComparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application.Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.Styrene maleic acid micelles as a nanocarrier system for oral anticancer drug delivery - dual uptake through enterocytes and M-cells.Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal functionAntiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract.The dipeptide monoester prodrugs of floxuridine and gemcitabine-feasibility of orally administrable nucleoside analogs.A Randomized, Open-Label, Two-Way Crossover, Single-Dose Bioequivalence Study of Temozolomide 200 mg/m(2) (Dralitem(®) vs. Temodal(®) Capsules) in Patients with Primary Tumors of the Central Nervous System Under Fasting Conditions.Improving anti-tumor activity of sorafenib tosylate by lipid- and polymer-coated nanomatrix.Novel dietary lipid-based self-nanoemulsifying drug delivery systems of paclitaxel with p-gp inhibitor: implications on cytotoxicity and biopharmaceutical performance.Impact of Undernutrition on the Pharmacokinetics and Pharmacodynamics of Anticancer Drugs: A Literature Review.Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation.Pharmacokinetics of hydroxymethylnitrofurazone, a promising new prodrug for Chagas' disease treatmentHyperbranched polydendrons: a new nanomaterials platform with tuneable permeation through model gut epithelium.Pathogenic Role of Exosomes in Epstein-Barr Virus (EBV)-Associated Cancers.Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar.Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends.
P2860
Q34570055-0CE60847-F7A0-40D2-A873-E39F09596AC1Q35154374-122F342D-1841-40E0-90E6-EFC07155FB06Q35167535-2C1F04B0-0E97-443C-AA02-AA825CB3EB98Q35892628-D0D1C67C-2F04-47D4-91C7-8E112415F06AQ35972223-E44F4276-2BD3-4711-BC73-4397FC249C76Q36097965-C812A375-8216-4CD3-814E-3473255D7F69Q37617635-A72BBD4E-BB92-4C31-ACBA-10DE0D61C92FQ38373115-63A7BCD9-74EF-4052-9669-5696F63C1738Q38717731-E0EDBC46-86A6-4568-B384-EE4E058BF350Q38856512-9DC5B269-9CC8-41CB-8923-4F8998373846Q38869469-47FAEC39-EBC1-465E-A371-819DE75CA47EQ40036535-E3AE0019-2BBF-4FDF-891C-3E3370A8586BQ42098034-F4B5CE02-C4C5-478C-83A6-A7AF2D2BC79DQ42238071-65CEDC57-65E4-4706-876B-01C00FBFB375Q45325266-9206C9A5-241F-4AA6-9812-807AA004ED97Q49179365-14879C4B-5A25-4C22-B822-3F716308EF21Q55278614-936F8731-48E5-4CFB-AD0A-A77B4EF18EB4
P2860
Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.
@en
type
label
Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.
@en
prefLabel
Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.
@en
P2093
P2860
P1476
Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement
@en
P2093
Bastiaan Nuijen
Jan H M Schellens
Jos H Beijnen
P2860
P2888
P304
P356
10.1007/S40262-013-0040-2
P577
2013-06-01T00:00:00Z
P6179
1051004374